Structural Analysis and Optimization of NK1 Receptor Antagonists through Modulation of Atropisomer Interconversion Properties

Journal of Medicinal Chemistry

Volumn 47, Issue 3, 2004, Pages 519-529

  Albert, Jeffrey S ^a   Ohnmacht, Cyrus ^a   Bernstein, Peter R ^a   Rumsey, William L ^a   Aharony, David ^a   Alelyunas, Yun ^a   Russell, Daniel J ^a   Potts, William ^a   Sherwood, Scott A ^a   Shen, Lihong ^a   Dedinas, Robert F ^a   Palmer, William E ^a   Russell, Keith ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 NAPHTHYL DERIVATIVE; FUNCTIONAL GROUP; N [2 (3,4 DICHLOROPHENYL) 3 AMINOCARBONYLPROPYL] N METHYL 3 CYANO 2 METHOXY 1 NAPHTHAMIDE; N [2 (3,4 DICHLOROPHENYL) 4 [4 (2 METHYLSULFINYLPHENYL) 1 PIPERIDINYL]BUTYL] N METHYL 3 CYANO 2 ETHYL 1 NAPHTHALAMIDE CITRATE; NEUROKININ 1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; ZD 4974; ZD 6021;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; ATROPISOMER; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOG; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONFORMATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GERBIL; ISOMER; MODEL; MODULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOPHORE; RECEPTOR AFFINITY; STRUCTURE ANALYSIS;

ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; CELL LINE, TUMOR; DOGS; GERBILLINAE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MODELS, MOLECULAR; NAPHTHALENES; PULMONARY ARTERY; RABBITS; RADIOLIGAND ASSAY; RECEPTORS, NEUROKININ-1; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 9144261575     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030197g     Document Type: Article

References (51)

1. Stout, S. C.; Owens, M. J.; Nemeroff, C. B. Neurokinin-1 receptor antagonists as potential antidepressants. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 877-906.
2. Chahl, L. A.; Urban, L. A. New developments in tachykinin research. Pharmacol. Rev. Commun. 1999, 10, 197-203.
3. Swain, C.; Rupniak, N. M. J. Progress in the development of neurokinin antagonists. Annu. Rep. Med. Chem. 1999, 34, 51-60.
4. 2 receptor antagonists. Drugs Future 1999, 24, 883-892.
5. Gao, Z.; Peet, N. P. Recent advances in neurokinin receptor antagonists. Curr. Med. Chem. 1999, 6, 375-388.
6. Sakurada, T.; Sakurada, C.; Tan-No, K.; Kisara, K. Neurokinin receptor antagonists: therapeutic potential in the treatment of pain syndromes. CNS Drugs 1997, 8, 436-447.
7. 2 antagonists. Bioorg. Med. Chem. Lett. 2001; 11, 2769-2773.
8. Rumsey, W. L.; Aharony, D.; Bialecki, R. A.; Abbott, B. M.; Barthlow, H. G.; Caccese, R.; Ghanekar, S.; Lengel, D.; McCarthy, M.; Wenrich, B.; Undem, B. ; Ohnmacht, C.; Shenvi, A.; Albert, J. S.; Brown, F.; Bernstein, P. R.; Russell, K. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors. J. Pharmacol. Exp. Ther. 2001, 298, 307-315.
9. Albert, J. S.; Aharony, D.; Andisik, D.; Barthlow, H.; Bernstein, P. R.; Bialecki, R. A.; Dedinas, R.; Dembofsky, B. T.; Hill, D.; Kirkland, K.; Koether, G. M.; Kosmider, B. J.; Ohnmacht, C.; Palmer, W.; Potts, W.; Rumsey, W.; Shen, L.; Shenvi, A.; Sherwood, S.; Warwick, P. J.; Russell, K. Design, synthesis, and SAR of tachykinin antagonists: Modulation of balance in NK1/ NK2 receptor antagonist activity. J. Med. Chem. 2002, 45, 3972-3983.
10. Testa, B.; Carrupt, P.-A.; Gal, J. The so-called " interconversion" of stereoisomeric drugs: an attempt at clarification. Chirality 1993, 5, 105-111.
11. Friary, R. J.; Spangler, M.; Osterman, R.; Schulman, L.; Schwerdt, J. H. Enantiomerization of an atropisomeric drug. Chirality 1996, 8, 364-371.
12. Hauser, F. M.; Sengupta, D.; Corlett, S. A. Optically active total synthesis of Calphostin D. J. Org. Chem. 1994, 59, 1967-1969.
13. Oki, M. The Chemistry of Rotatonal Isomers; Springer-Verlag: New York, 1993.
14. Ahmed, A.; Bragg, R. A.; Clayden, J.; Lai, L. W.; McCarthy, C.; Pink, J. H.; Westlund, N.; Yasin, S. A. Barriers to rotation about the chiral axis of tertiary aromatic amides. Tetrahedron 1998, 54, 13277-13294.
15. Clayden, J.; McCarthy, C.; Helliwell, M. Bonded peri-interactions govern the rate of racemization of atropisomeric 8-substituted 1-naphthamides. Chem. Commun. 1999, 2059-2060.
16. Clayden, J.; Pink, J. H. Concerted rotation in a tertiary aromatic amide: towards a simple molecular gear. Angew. Chem., Int. Ed. 1998, 37, 1937-1939.
17. For compounds that displayed nonpurely competitive antagonism, activity could be estimated by monitoring the magnitude of the maximum tissue relaxation response (percent of control response) to increasing agonist concentration following incubation of the tissue with the antagonist at a given concentration. Values are expressed as percent inhibition, which is calculated by (100 - percentage of control response). Thus, greater antagonist potency would be indicated by greater percent inhibition and at lower antagonist concentration.
18. Rupniak, N. M. J.; Tattersall, F. D.; Williams, A. R.; Rycroft, W.; Carlson, E. J.; Cascieri, M. A.; Sadowski, S.; Ber, E.; Hale, J. J.; Mills, S. G.; MacCoss, M.; Seward, E.; Huscroft, I.; Owen, S.; Swain, C. J.; Hill, R. G.; Hargreaves, R. J. In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists. Eur. J. Pharmacol. 1997, 326, 201-209.
19. Iwamura, H.; Mislow, K. Stereochemical consequences of dynamic gearing. Acc. Chem. Res. 1988, 21, 175-182.
20. Manuscript in preparation.
21. Swain, C. J.; Sewart, E. M.; Cascieri, M. A.; Fong, T. M.; Herbert, R.; MacIntyre, D. E.; Merchant, K. J.; Owen, S. N., Owens, A. P.; et al. Identification of a series of 3-(benzyloxy)1-azabicyclo-[2.2.2]octane human NK1 antagonists. J. Med. Chem. 1995, 38, 4793-4805.
22. Lowe, J. A., III; Drozda, S. E.; Snider, R. M.; Longo, K. P.; Zorn, S. H.; Morrone, J.; Jackson, E. R.; McLean, S.; Bryce, D. K.; et al. The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2] octan-3-amine as a novel, nonpeptide substance P antagonist. J. Med. Chem. 1992, 35, 2591-2600.
23. Boks, G. J.; Tollenaere, J. P.; Kroon, J. Possible ligand-receptor interactions for NK1 antagonists as observed in their crystal structures. Bioorg. Med. Chem. 1997, 5, 535-547.
24. Caliendo, G.; Grieco, P.; Perissutti, E.; Santagada, V.; Saviano, G.; Tancredi, T.; Temussi, P. A. Conformational analysis of three NK1 tripeptide antagonists: A proton nuclear magnetic resonance study. J. Med. Chem. 1997, 40, 594-601.
25. Veenstra, S. J.; Hauser, K.; Betschart, C. Studies on the active conformation of NK1 antagonist CGP 49823. Part 1. Synthesis of conformationally restricted analogs. Bioorg. Med. Chem. Lett. 1997, 7, 347-350.
26. Desai, M. C.; Lefkowitz, S. L.; Thadeio, P. F.; Longo, K. P.; Snider, R. M. Discovery of a potent substance P antagonist: recognition of the key molecular determinant. J. Med. Chem. 1992, 35, 4911-4913.
27. Stevenson, G. I.; Huscroft, I.; MacLeod, A. M.; Swain, C. J.; Cascieri, M. A.; Chicchi, G. G.; Graham, M. I.; Harrison, T.; Kelleher, F. J.; Kurtz, M.; Ladduwahetty, T.; Merchant, K. J.; Metzger, J. M.; MacIntyre, D. E.; Sadowski, S.; Sohal, B.; Owens, A. P. 4,4-Disubstituted piperidine high-affinity NK1 antagonists: Structure-activity relationships and in vivo activity. J. Med. Chem. 1998, 41, 4623-4635.
28. Lewis, R. T.; Macleod, A. M.; Merchant, K. J.; Kelleher, F.; Sanderson, I.; Herbert, R. H.; Cascieri, M. A.; Sadowski, S.; Ball, R. G.; Hoogsteen, K. Tryptophan-derived NK1 antagonists: Conformationally constrained heterocyclic bioisosteres of the ester linkage. J. Med. Chem. 1995, 38, 923-933.
29. Ikeura, Y.; Ishichi, Y.; Tanaka, T.; Fujishima, A.; Murabayashi, M.; Kawada, M.; Ishimaru, T.; Kamo, I.; Doi, T.; Natsugari, H. Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1,7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: Determination of the absolute stereochemical requirements. J. Med. Chem. 1998, 41, 4232-4239.
30. Sisto, A.; Bonelli, F.; Centini, F.; Fincham, C. I.; Potier, E.; Monteagudo, E.; Lombardi, P.; Arcamone, F.; Goso, C.; et al. Synthesis and biological evaluation of novel NK-1 tachykinin receptor antagonists: the use of cycloalkyl amino acids as a template. Biopolymers 1995, 36, 511-524.
31. Greenfeder, S.; Cheewatrakoolpong, B.; Anthes, J.; Billah, M.; Egan, R. W.; Brown, J. E.; Murgolo, N. J. Two related neurokinin-1 receptor antagonists have overlapping but different binding sites. Bioorg. Med. Chem. 1998, 6, 189-194.
32. Jacoby, E.; Boudon, A.; Kucharczyk, N.; Michel, A.; Fauchere, J.-L. A structural rationale for the design of water soluble peptide-derived neurokinin-1 antagonists. J. Recept. Signal Transduction Res. 1997, 17, 855-873.
33. Takeuchi, Y.; Shands, E. F. B.; Beusen, D. D.; Marshall, G. R. Derivation of a 3-dimensional pharmacophore model of substance P antagonists bound to the neurokinin-1 receptor. J. Med. Chem. 1998, 41, 3609-3623.
34. Hale, J. J.; Mills, S. G.; MacCoss, M.; Finke, P. E.; Cascieri, M. A.; Sadowski, S.; Ber, E.; Chicchi, G. G.; Kurtz, M.; Metzger, J.; Eiermann, G.; Tsou, N. N.; Tattersall, F. D.; Rupniak, N. M. J.; Williams, A. R.; Rycroft, W. ; Hargreaves, R.; MacIntyre, D. E. Structural optimization affording 2-(R)-(1-(R)-3,5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro) phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J. Med. Chem. 1998, 41, 4607-4614.
35. Kramer, M. S.; Cutler, N.; Feighner, J.; Shrivastava, R.; Carman, J.; Sramek, J. J.; Reines, S. A.; Liu, G.; Snavely, D.; Wyatt-Knowles, E.; Hale, J. J.; Mills, S. G.; MacCoss, M.; Swain, C. J.; Harrison, T.; Hill, R. G.; Hefti, F.; Scolnick, E. M.; Cascieri, M. A.; Chicchi, G. G.; Sadowski, S.; Williams, A. R.; Hewson, L.; Smith, D.; Carlson, E. J.; Hargreaves, R. J.; Rupniak, N. M. J. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (Washington, D.C.) 1998, 281, 1640-1645.
36. Seward, E. M.; Carlson, E.; Harrison, T.; Haworth, K. E.; Herbert, R.; Kelleher, F. J.; Kurtz, M. M.; Moseley, J.; Owen, S. N.; Owens, A. P.; Sadowski, S. J.; Swain, C. J.; Williams, B. J. Spirocyclic NK1 antagonists I: [4.5] and [5.5]-spiroketals. Bioorg. Med. Chem. Lett. 2002, 12, 2515-2518.
37. CATALYST, version 4.5; Molecular Simulations Inc.: San Diego, CA.
38. Aharony, D.; Little, J.; Thomas, C.; Powell, S.; Berry, D.; Graham, A. Isolation and pharmacological characterization of a hamster urinary bladder neurokinin A receptor cDNA. Mol. Pharmacol. 1994, 45, 9-19.
39. Graham, A.; Hopkins, B.; Powell, S. J.; Danks, P.; Briggs, I. Isolation and characterization of the human lung NK-2 receptor gene using rapid amplification of cDNA ends. Biochem. Biophys. Res. Commun. 1991, 177, 8-16.
40. Huang, R.; Cheung, A.; Mazina, K.; Strader, C.; Fong, T. cDNA Sequence and heterologous expression of the human neurokinin-3 receptor. Biochem. Biophys. Res. Commun. 1992, 184, 966-972.
41. Takeda, Y.; Chou, K. B.; Takeda, J.; Sachais, B. S.; Krause, J. E. Molecular cloning, structural characterization and functional expression of the human substance P receptor. Biochem. Biophys. Res. Commun. 1991, 179, 1232-1240.
42. Fong, T. M.; Anderson, S. A.; Yu, H.; Huang, R. R. C.; Strader, C. D. Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol. Pharmacol. 1992, 41, 24-30.
43. Gerard, N. P.; Garraway, L. A.; Eddy, R. L., Jr.; Shows, T. B.; Iijima, H.; Paquet, J. L.; Gerard, C. Human substance P receptor (NK-1): organization of the gene, chromosome localization and functional expression of cDNA clones. Biochemistry 1991, 30, 10640-10646.
44. Takahashi, K.; Tanaka, A.; Hara, M.; Nakanishi, S. The primary structure and gene organization of human substance P and neuromedin K receptors. Eur. J. Biochem. 1992, 204, 1025-1033.
45. Buell, G.; Schulz, M. F.; Arkinstall, S. J.; Maury, K.; Missotten, M.; Adami, N.; Talabot, F.; Kawashima, E. Molecular characterization, expression and localization of human neurokinin-3 receptor. FEBS Lett. 1992, 299, 90-95.
46. Aharony, D.; Buckner, C. K.; Ellis, J. L.; Ghanekar, S. V.; Graham, A.; Kays, J. S.; Little, J.; Meeker, S.; Miller, S. C.; et al. Pharmacological characterization of a new class of nonpeptide neurokinin A antagonists that demonstrate species selectivity. J. Pharmacol. Exp. Ther. 1995, 274, 1216-1221.
47. AESOP is an in-house molecular mechanics program (Masek, B.) derived from BIGSTRN-3 (QCPE-514): Nachbar, R., Jr.; Mislow, K. QCPE Bull. 1986, 6, 96.
48. ENIGMA is an in-house molecular graphics program.
49. Miller, S. C. (Zeneca Ltd., U.K.). Novel 4-piperidinyl-substituted lactams as neurokinin 2 receptor antagonists for the treatment of asthma. PCT Int. Appl. WO 9512577, 1995.
50. Corey, E. J.; Schmidt, G. Useful procedures for the oxidation of alcohols involving pyridinium dichromate in aprotic media. Tetrahedron Lett. 1979, 399-402.
51. Bajusz, S.; Ronai, A. Z.; Szekely, J. I.; Graf, L.; Dunai-Kovacs, Z.; Berzetei, I. A superactive antinociceptive pentapeptide, (D-Met2, Pro5)-enkephalinamide. FEBS Lett. 1977, 76, 91-92.